150 related articles for article (PubMed ID: 23351371)
1. Pre-existence and emergence of drug resistance in a generalized model of intra-host viral dynamics.
Alexander HK; Bonhoeffer S
Epidemics; 2012 Dec; 4(4):187-202. PubMed ID: 23351371
[TBL] [Abstract][Full Text] [Related]
2. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV.
Locarnini S; Warner N
Antivir Ther; 2007; 12 Suppl 3():H15-23. PubMed ID: 18284179
[TBL] [Abstract][Full Text] [Related]
3. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
Guedj J; Neumann AU
J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
[TBL] [Abstract][Full Text] [Related]
4. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
[TBL] [Abstract][Full Text] [Related]
5. Is hepatitis virus resistance to antiviral drugs a threat?
Pawlotsky JM
Gastroenterology; 2012 May; 142(6):1369-72. PubMed ID: 22537445
[No Abstract] [Full Text] [Related]
6. Comparison of antiviral resistance across acute and chronic viral infections.
Mason S; Devincenzo JP; Toovey S; Wu JZ; Whitley RJ
Antiviral Res; 2018 Oct; 158():103-112. PubMed ID: 30086337
[TBL] [Abstract][Full Text] [Related]
7. Antiviral combination therapy for treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency virus infection.
Hofmann WP; Soriano V; Zeuzem S
Handb Exp Pharmacol; 2009; (189):321-46. PubMed ID: 19048206
[TBL] [Abstract][Full Text] [Related]
8. [Genotype distribution of chronic hepatitis B and hepatitis C patients and investigation of the resistance patterns in hepatitis B cases].
Kalayci R; Altindiş M; Gülamber G; Demirtürk N; Akcan Y; Demirdal T
Mikrobiyol Bul; 2010 Apr; 44(2):237-43. PubMed ID: 20549958
[TBL] [Abstract][Full Text] [Related]
9. Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis.
Soriano V; Barreiro P; Martín-Carbonero L; Castellares C; Ruiz-Sancho A; Labarga P; Ramos B; Gonzalez-Lahoz J
J Infect Dis; 2007 Apr; 195(8):1181-3. PubMed ID: 17357055
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection.
Asmuth DM; Busch MP; Laycock ME; Mohr BA; Kalish LA; van der Horst CM;
Antiviral Res; 2004 Aug; 63(2):123-31. PubMed ID: 15302141
[TBL] [Abstract][Full Text] [Related]
11. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.
van der Eijk AA; Hansen BE; Niesters HG; Janssen HL; van de Ende M; Schalm SW; de Man RA
J Viral Hepat; 2005 Jul; 12(4):364-72. PubMed ID: 15985006
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.
Santos EA; Sucupira MV; Arabe J; Gomes SA
BMC Infect Dis; 2004 Aug; 4():29. PubMed ID: 15339340
[TBL] [Abstract][Full Text] [Related]
13. Designing a low-cost drug resistance database for viral hepatitis.
Kuiken C
Antivir Ther; 2010; 15(3 Pt B):517-20. PubMed ID: 20516573
[TBL] [Abstract][Full Text] [Related]
14. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
16. Understanding the pathogenesis and management of hepatitis B/HIV and hepatitis B/hepatitis C virus coinfection.
Cheruvu S; Marks K; Talal AH
Clin Liver Dis; 2007 Nov; 11(4):917-43, ix-x. PubMed ID: 17981235
[TBL] [Abstract][Full Text] [Related]
17. Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases.
Nijhuis M; van Maarseveen NM; Boucher CA
Handb Exp Pharmacol; 2009; (189):299-320. PubMed ID: 19048205
[TBL] [Abstract][Full Text] [Related]
18. Coevolution and HBV drug resistance.
Khudyakov Y
Antivir Ther; 2010; 15(3 Pt B):505-15. PubMed ID: 20516572
[TBL] [Abstract][Full Text] [Related]
19. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
Halfon P; Sarrazin C
Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
[TBL] [Abstract][Full Text] [Related]
20. Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy.
Lee SH; Kim HS; Byun IS; Jeong SW; Kim SG; Jang JY; Kim YS; Kim BS
J Med Virol; 2012 Feb; 84(2):217-22. PubMed ID: 22170540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]